PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-10.40%
Both companies show declining cash positions (-10.40% vs AVXL's -8.63%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-10.40%
Cash + STI yoy 1.25-1.5x AVXL's -8.63%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AVXL's -23.63%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-10.80%
1.25-1.5x AVXL's -8.50%. Bruce Berkowitz checks if strong current asset growth is used effectively.
-9.91%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.93%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-8.44%
Below half of AVXL's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
1.25-1.5x AVXL's -8.50%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.85%
Less than half of AVXL's 32.29%. David Dodd sees fewer expansions in other current obligations.
-12.74%
Similar yoy to AVXL's -14.22%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.42%
Less than half of AVXL's 59.92%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Less than half of AVXL's -14.22%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.24%
1.25-1.5x AVXL's -3.60%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.56%
≥ 1.5x AVXL's -7.77%. David Dodd sees stronger capital base growth than competitor.
-10.73%
1.25-1.5x AVXL's -8.50%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
-8.90%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
10.43%
1.1-1.25x AVXL's 8.63%. Bill Ackman questions if net debt is increasing faster than competitor.